Human herpesvirus-8 (HHV-8/KSHV) is etiologically associated with Kaposi's sarcoma (KS) and other tumors. Constitutive activation of the mitogen-activated protein kinase (MAPK) signaling pathway has been associated with a variety of tumors, including AIDS-related KS. The oncoprotein Raf is situated at a pivotal position in regulating the MAPK pathway. Hence, we analysed the effect of oncoprotein Raf on HHV-8 infectious entry into target cells. Here we report Raf expression to significantly enhance HHV-8 infection of target cells. These findings implicate a role for Raf not only in the infectious entry of HHV-8 but also in modulating KS pathogenesis.
Introduction
Human herpesvirus 8 (HHV-8) or Kaposi's sarcoma (KS)-associated herpesvirus (KSHV) is a newly discovered herpesvirus. HHV-8 is a member of the lymphoproliferative human g2-herpesvirus family (genus Rhadinovirus) (Russo et al., 1996) , which was first identified by representation difference analysis of KS tissue from an AIDS patient in 1994 (Chang et al., 1994) . HHV-8 is an important pathogen capable of causing disease that affects all age groups worldwide (Gallo, 1998) . HHV-8 is associated with all forms of KS, body cavity lymphomas, multicentric Castleman's Disease (MCD), and recently it has been suggested to be associated with myeloma, sarcoidosis, salivary gland tumors and other malignancies (Ablashi et al., 2002) . The use of highly active antiretroviral therapy (HAART) since 1996 has markedly reduced the prevalence of AIDS in western countries, but because 99% of the 40 million patients with AIDS in the world cannot afford HAART, KS is still a very common problem (Geraminejad et al., 2002) .
HHV-8 infects a variety of target cells. However, there are no primary cells or cell lines that are readily permissive for HHV-8 infection or are they known to produce high quantities of infectious virus in vitro (Blackbourn et al., 2000; Cerimele et al., 2001; Vieira et al., 2001) . In vivo, productive (lytic) infection is restricted to only a small fraction of cells at any given point of KS progression (Blasig et al., 1997; Sirianni et al., 1997; Morand et al., 1999) .
Studies have indicated that both a disturbance of the immune system and infection by HHV-8 are two major risk factors for KS development (Ensoli et al., 2001) . KS is a neoplasm of vascular origin arising as multiple independent lesions, and over time, can progress into a nodular tumor localizing in skin and visceral organs including the gastro-intestinal tract and lungs (Ensoli et al., 2001) . Tumors arise owing to the accumulation of mutations in critical genes that alter normal programs of cell proliferation, differentiation, and death. The Ras/ Raf/MEK/ERK pathway also called as the mitogenactivated protein kinase (MAPK) pathway, regulates a variety of cellular processes, including embryogenesis, proliferation, differentiation, and apoptosis, among others each of which plays a significant role in tumorigenesis (Peyssonnaux and Eychene, 2001; Hilger et al., 2002) . Directly downstream of Ras is Raf. Raf is located at a pivotal position acting to relay signals from activated Ras proteins via MEK1/2 to ERK1/2, the key effectors of this pathway (Marshall, 1996; SeboltLeopold, 2000) . Small GTPases, kinases, phosphatases, scaffolding proteins, and 14-3-3 regulate the MAPK pathway through their effects on Raf activity (Chong et al., 2003) . Raf has been identified as an oncogene in human cancers (Davies et al., 2002) . Recently, B-Raf somatic missence mutations have been detected in malignant melanomas (66%) and colon cancers (15%) and at lower frequencies in a wide variety of human cancers (Davies et al., 2002) . Interestingly, a broad array of solid tumors are known to express constitutively phosphorylated ERK1/2, which is a downstream event of Ras/Raf activation (Mercer and Pritchard, 2003) ; and constitutive activation of the components (Ras/Raf) of the MAPK pathway have been associated with a variety of tumors; including AIDS-related KS (Faris et al., 1996) . However, there is very little research performed on the effect of such oncogenic signals on virus infections.
In this paper, we provide several lines of evidence demonstrating the ability of the Raf oncoprotein to enhance HHV-8 infectious entry into target cells via modulating growth factor expression. Our hypothesis that 'Raf oncoprotein leads to enhanced HHV-8 infectious entry' was tested using an in vitro cell culture model to study virus binding, entry, and infection in a condition that mimics, at least in part, the KS lesion. The strategy was to use DRaf:ER fusion proteins (Samuels et al., 1993) to study the functions of different Raf oncoproteins as described earlier. The DRaf:ER constructs lack both CR1 (Ras-binding domain) and CR2 (negative regulating domain) domains, and the CR3 domain was fused with the hormone-binding domain of estrogen receptor protein. Hence, these DRaf:ER fusion proteins become active upon b-estradiol treatment. Upon b-estradiol stimulation, DRaf:ERs have been shown to specifically activate the downstream targets of Raf molecule, MEK1/2 and ERK1/2 (McCubrey et al., 1998; Hoyle et al., 2000) . This system has been exploited successfully and extensively by others to study the roles of Raf in cancer biology (McCarthy et al., 1997; McCubrey et al., 1998; Hoyle et al., 2000; Chang and McCubrey, 2001; Le Gall et al., 2003) .
Results

Characterizing the activation of the three Raf oncoproteins and their downstream targets MEK1/2, ERK1/2 in Raf-expressing PA317 and HFF cells
There are three related Raf genes in the mammals: ARaf, B-Raf and Raf-1 (Kolch, 2000; Chong et al., 2003) . Previously it was demonstrated that the levels of DRaf:ER activity increased in murine hematopoietic FDC-P1 cells when treated with 1 mM b-estradiol when compared to untreated cells (Chang and McCubrey, 2001) . In this study, we used PA317 (packaging cell line expressing an amphotropic murine retrovirus Env protein) cells conditionally expressing various Raf oncoproteins (Table 1) to determine the effect of Raf on HHV-8 infectious entry. The presence of activated DRaf:ER, MEK, and ERK expression in these cells was determined. DRaf:ER kinase activity was not detected in the unstimulated PA317, PA317/DA-Raf [DD] :ER, PA317/DA-Raf [FF] :ER, PA317/DA-Raf [YY] :ER, PA317/ DB-Raf [DD] :ER, PA317/DB-Raf [FF] :ER, PA317/DBRaf [YY] :ER, PA317/DRaf-1 [DD] :ER, PA317/DRaf-1 [FF] :ER, PA317/DRaf-1 [YY] :ER ( Figure 1a , lanes 1-10) or PA317/pBabePuro3 (empty vector) cells (data not shown). In b-estradiol-stimulated cells, significant DRaf:ER kinase activity was observed in PA317/ DA-Raf [DD] :ER, PA317/DA-Raf [YY] :ER, PA317/DBRaf [DD] :ER, PA317/DB-Raf [YY] :ER, PA317/DRaf-1 [DD] :ER, PA317/DRaf-1 [YY] :ER (Figure 1b, lanes 2, 4, 5, 7, 8, and 10) . Onefold higher DRaf:ER kinase activity was observed in b-estradiol-stimulated PA317/ DB-Raf [DD] :ER, PA317/DB-Raf [YY] :ER, and PA317/ DRaf-1 [DD] :ER (Figure 1b , lanes 5, 7, and 8) when compared to PA317/DA-Raf [DD] :ER, PA317/DARaf [YY] :ER, and PA317/DRaf-1 [YY] :ER cells (Figure 1b , lanes 2, 4, and 10). We did not observe DRaf:ER kinase activity in b-estradiol-stimulated PA317, PA317/ DA-Raf [FF] :ER, PA317/DB-Raf [FF] :ER, PA317/DRaf-1 [FF] :ER ( Figure 1b , lanes 1, 3, 6, and 9), and PA317/ pBabePuro3 cells (data not shown). These results point to the fact that there is differential activation among the different Raf genes. The rank order of kinase activity was PA317/DB-Raf [DD] :ER4PA317/DRaf-1 [YY] :ER and PA317/DA-Raf [YY] :ER. The DRaf:ER kinase activity detected in both PA317/DB-Raf [DD] :ER and PA317/ DB-Raf [YY] :ER was comparable (Figure 1b , lanes 5 and 7). However, DRaf:ER kinase activity dropped significantly when the wild-type phosphorylation residue [DD] was mutated to [FF] as observed in PA317/DBRaf [FF] :ER (Figure 1b , lane 6) demonstrating that the B-Raf protein activity could be either unaltered (DD to YY) or altered negatively (DD to FF) by mutating the regulatory phosphorylation sites. Similarly, DRaf:ER kinase activity in PA317/DRaf-1 [YY] :ER (Figure 1b (Marshall, 1996; Lee and McCubrey, 2002) . Activation of MEK and ERK is through phosphorylation and hence phosphorylation-specific antibodies were used to measure the activation of MEK and ERK levels in PA317 cells expressing different Raf oncoproteins, when either unstimulated or stimulated with b-estradiol. Basal levels of MEK1/2 and ERK1/2 activity were detected in unstimulated PA317 and various PA317 cells expressing different Raf oncoproteins ( Figure 1a, lanes 1-10) . Similar levels were observed in PA317/pBabePuro3 cells (data not shown). The basal level observed in these cells is due to the inherent cellular MAPK pathway of signaling that was independent of the DRaf:ER kinase activity. In bestradiol-stimulated cells, we observed significantly higher levels of MEK1/2 and ERK1/2 activity in PA317/DB-Raf [DD] :ER, PA317/DB-Raf [YY] :ER, and PA317/DRaf-1 [DD] :ER (Figure 1b , lanes 5, 7, and 8) when compared to PA317/DA-Raf [DD] :ER, PA317/DARaf [YY] :ER, and PA317/DRaf-1 [YY] :ER cells (Figure 1b, lanes 2, 4, and 10). However, there was no significant increase in the level of MEK1/2 and ERK1/2 activity noted in b-estradiol-stimulated PA317, PA317/DARaf [FF] :ER, PA317/DB-Raf [FF] :ER, PA317/DRaf-1 [FF] :ER ( Figure 1b, lanes 1, 3, 6 , and 9) and PA317/ pBabe/Puro3 cells (data not shown) when compared to the unstimulated cells (Figure 1a) .
These findings were reproduced in human foreskin fibroblast (HFF) conditionally expressing DRaf:ER proteins. HFF cells were used in this study for two reasons: (1) HFF cells support HHV-8 infection that can be easily monitored (Akula et al., 2001b; Vieira et al., 2001) ; and (2) HFF can be grown in medium that does not require additional supplement of growth factors that may interfere with the results. The cells used in the following experiments were HFF, HFF/pBabePuro3, HFF/DA-Raf [YY] :ER, HFF/DB-Raf [DD] :ER, and HFF/ DRaf-1 [YY] :ER which contained the wild-type phosphorylation domain. DRaf:ER, MEK, and ERK expression was examined in these cells as described above (Figure 1a and b) . DRaf:ER kinase activity was not detected in the unstimulated HFF, HFF/DA-Raf [YY] :ER, HFF/DB-Raf [DD] :ER, HFF/DRaf-1 [YY] :ER ( Figure 2a, lanes 1-4) , and HFF/pBabePuro3 cells (data not shown). In b-estradiol-stimulated cells, significant In all, 100 mg of unstimulated (a) or b-estradiol stimulated (b) PA317, PA317/DA-Raf [DD] :ER, PA317/DA-Raf [FF] :ER, PA317/DA-Raf [YY] :ER, PA317/DB-Raf [DD] :ER, PA317/DB-Raf [FF] :ER, PA317/DB-Raf [YY] :ER, PA317/DRaf-1 [DD] :ER, PA317/DRaf-1 [FF] :ER, and PA317/DRaf-1 [YY] :ER cell lysates were subjected to Raf kinase assay to monitor the DRaf:ER activity. In another set of experiments, 25 mg of cell lysates were used in Western blotting experiments to determine the presence of phosphor-MEK1/2, MEK1/2, phosphor-ERK1/2, ERK1/2, and b-actin. Data representing the protein activity are presented as fold increase (average7s.d. from three experiments) in the boxes below the panels DRaf:ER kinase activity was detected in HFF/DARaf [YY] :ER, HFF/DB-Raf [DD] :ER, and HFF/DRaf-1 [YY] :ER ( Figure 2b , lanes 2-4). We reproducibly detected higher levels of DRaf:ER kinase activity in HFF/DB-Raf [DD] :ER (Figure 2b , lane 3) when compared to HFF/DA-Raf [YY] :ER and HFF/DRaf-1 [YY] :ER cells ( Figure 2b , lanes 2 and 4). There was no DRaf:ER kinase activity detected in b-estradiol-stimulated HFF (Figure 2b , lane 1) and HFF/pBabePuro3 cells (data not shown). The rank order of kinase activity was HFF/DBRaf [DD] :ER4HFF/DRaf-1 [YY] :ER and HFF/DA-Raf [YY] :ER. This order was consistent with the observed strengths of the different Raf kinases expressed in PA317 cells (Figure 1b) .
A basal level of MEK1/2 and ERK1/2 activity was detected in unstimulated HFF, HFF/DA-Raf [YY] :ER, HFF/DB-Raf [DD] :ER, and HFF/DRaf-1 [YY] :ER ( Figure 2a, lanes 1-4) . Similar levels were observed in HFF/pBabePuro3 cells (data not shown). The basal level observed in these cells could be due to the inherent cellular MAPK pathway of signaling that was independent of the DRaf:ER kinase activity. In b-estradiolstimulated cells, we detected significantly higher levels of MEK1/2 and ERK1/2 activity in HFF/DA-Raf [YY] :ER, HFF/DB-Raf [DD] :ER, and HFF/DRaf-1 [YY] :ER when compared to HFF cells (Figure 2b) . Interestingly, the MEK1/2 and ERK1/2 activity observed in HFF/DBRaf [DD] :ER cells (Figure 2b , lane 3) was significantly higher when compared to HFF/DA-Raf [YY] :ER, and HFF/DRaf-1 [YY] :ER cells (Figure 2b, lanes 2 and 4) . Equal loading of total lysate between the treatments were confirmed by Western blot reactions with antibodies against the total MEK1/2, ERK1/2, and b-actin protein (Figures 1 and 2) . These results also confirmed that the protein levels of endogenous MEK1/2 and ERK1/2 remained relatively constant and were not increased due to the activation of DRaf:ER. A direct correlation between Raf kinase activity and the downstream events involving MEK1/2 and ERK1/2 activity was observed (Figures 1 and 2) . The results on Raf kinase and MAPK activity observed by the use of various DRaf:ER constructs in PA317 and HFF cells were comparable to what was reported earlier as a measure of transforming capacity (Hoyle et al., 2000) .
Activated Raf proteins enhances HHV-8 infection of PA317 and HFF cells
To examine how the activity of the DRaf:ER protein altered HHV-8 binding and infection, the ability of HHV-8 to infect PA317, PA317/pBabePuro3, PA317/ DA-Raf [DD] :ER, PA317/DA-Raf [FF] :ER, PA317/DARaf [YY] :ER, PA317/DB-Raf [DD] :ER, PA317/DB-Raf [FF] : ER, PA317/DB-Raf [YY] :ER, PA317/DRaf-1 [DD] :ER, PA317/DRaf-1 [FF] :ER, and PA317/DRaf-1 [YY] :ER cells was determined. Raf enhanced recombinant green fluorescence protein expressing HHV-8 (GFP-HHV-8) infection of cells (Figure 3a) . At the end of 3 days postinfection (DPI), approximately 250 green fluorescent cells indicative of infection in PA317 and PA317/ pBabePuro3 were observed. No significant change in the HHV-8 infection pattern of the various unstimulated PA317 cells was observed (Figure 3a) . In b-estradiolstimulated cells, HHV-8 infection was significantly enhanced in PA317/DA-Raf [DD] :ER, PA317/DARaf [YY] :ER, PA317/DB-Raf [DD] :ER, PA317/DB-Raf [YY] : ER, PA317/DRaf-1 [DD] :ER, and PA317/DRaf-1 [YY] :ER. There was no significant enhancement of HHV-8 infection observed in b-estradiol-stimulated PA317, PA317/ DA-Raf [FF] :ER, PA317/DB-Raf [FF] :ER, PA317/DRaf-1 [FF] :ER (Figure 3a) , and PA317/pBabePuro3 (data not shown) cells. These results were further confirmed by performing immunoperoxidase assays and reverse transcription-polymerase chain recation (RT-PCR) to detect ORF73 expression in infected cells (data not shown). These results demonstrated a conclusive link between enhancement of HHV-8 infection and expression of DRaf:ER protein in PA317 cells. The rank order of enhanced HHV-8 infection observed in PA317 cells was DB-Raf:ER4DRaf-1:ER4DA-Raf:ER. [YY] :ER, HFF/DBRaf [DD] :ER, and HFF/DRaf-1 [YY] :ER cell lysates were subjected to Raf kinase assay. In another set of experiments, 25 mg of cell lysates were probed by Western blotting for the presence of phosphor-MEK1/2, MEK1/2, phosphor-ERK1/2, ERK1/2, and b-actin. Data representing the protein activity are presented as fold increase (average7s.d. from any three experiments) in the boxes below the panels In order to elucidate the specificity of activated Raf oncoproteins in enhancing HHV-8 infection of cells, the ability of GFP-HHV-8 to infect PA317/Raf-1 and PA317/DRaf-1 cells (Table 1 ) was compared. The difference between these two cells is that PA317/Raf-1 cells contain the Raf-1 wild-type oncogene while PA317/ DRaf-1 cells have a constitutively active Raf-1 oncogene, which lacks the ER domain. GFP-HHV-8 infection of PA317/DRaf-1 was threefold higher than that observed in PA317/Raf-1 cells (Figure 3b ). This enhanced infection is due to constitutive expression of Raf-1 gene in PA317/DRaf-1 cells when compared to PA317/Raf-1 cells.
The ability of HHV-8 to infect HFF, HFF/pBabePuro3, HFF/DA-Raf [YY] :ER, HFF/DB-Raf [DD] :ER, and HFF/DRaf-1 [YY] :ER cells was determined. TCID 50 of HSV-2 was produced in HFF cells. This data also demonstrated the specificity of the effect of Raf oncoproteins on HHV-8 infection. Taken together, these results implicate Raf oncoprotein to specifically and significantly enhance HHV-8 infection of cells. The rank order of enhanced HHV-8 infection observed in HFF cells was DB-Raf:ER4DRaf-1:ER4DA-Raf:ER. Although a significant difference between the DRaf:ER activity was not observed in PA317 or HFF/DARaf [YY] :ER, and PA317 or HFF/DRaf-1 [YY] :ER, respectively ( Figure 1b , lanes 4 and 10; Figure 2b , lanes 2 and 4), there was a significant difference in the HHV-8 infection of these cells. We hypothesize this to be due to the sensitivity of our assay employed to detect minute differences in DRaf:ER activity.
Inhibition of MEK suppresses HHV-8 infection
The Raf/MEK/ERK pathway can be inhibited by targeting MEK (Hilger et al., 2002; Lee and McCubrey, 2002) . UO126 is one of the commonly used small molecule inhibitors of MEK activity. This compound binds inactive MEK isoforms, thereby preventing effective phosphorylation through their upstream (Hilger et al., 2002; Lee and McCubrey, 2002) . UO126 treatment (10 mM) of unstimulated PA317 cells expressing various Raf proteins, lowered MEK1/2 and ERK1/2 phosphorylation to almost undetectable levels (data not shown). UO126 treatment also lowered MEK1/2 and ERK1/2 phosphorylation to almost undetectable levels in b-estradiol-stimulated PA317, PA317/DA:Raf [FF] :ER, PA317/DB-Raf [FF] :ER, and PA317/DRaf-1 [FF] :ER; by about 2.5-and 3.5-fold in PA317/DA-Raf [DD] :ER, PA317/DA-Raf [YY] :ER, and PA317/DRaf-1 [YY] :ER; 3.0-and 4.5-fold in PA317/DBRaf [DD] :ER, PA317/DB-Raf [YY] :ER, PA317/DRaf-1 [DD] :ER cells, respectively. The requirement of MEK activity in HHV-8 infection of PA317 cells was next investigated. A dose-dependent inhibition of HHV-8 infection was observed in various b-estradiol-stimulated PA317 cells expressing Raf, upon UO126 treatment. A maximal inhibition was observed when UO126 was used at a concentration of 10 mM (Table 2) . No significant inhibition in HHV-8 infection of cells when DMSO, the vehicle for UO126, was used in place of UO126 (data not shown).
A dose-dependent inhibition of ERK1/2 phosphorylation by UO126 in HFF cells was observed. A significant drop in the activity of ERK1/2 was observed when HFF, HFF/DA-Raf [YY] :ER, HFF/DB-Raf [DD] :ER (data not shown), and HFF/DRaf-1 [YY] :ER cells ( Figure 4) were treated with 5 and 10 mM UO126. UO126 (10 mM) treatment of unstimulated HFF cells expressing various Raf proteins, lowered MEK1/2 and ERK1/2 phosphorylation to almost undetectable levels (data not shown). In b-estradiol-stimulated HFF cells, UO126 treatment lowered MEK1/2 and ERK1/2 phosphorylation to almost undetectable levels; by about 3.0-and 3.5-fold in HFF/DA-Raf [YY] :ER, and HFF/ DRaf-1 [YY] :ER; and by about 4.0-and 4.5-fold in HFF/ DB-Raf [DD] :ER cells, respectively. These results confirm the specificity of UO126 to inhibit phosphorylation of MEK1/2 and not the availability of the endogenous MEK1/2 levels. A dose responsive inhibition of HHV-8 infection in various b-estradiol-stimulated HFF cells was also observed upon UO126 treatment (Table 3) . No significant inhibition in HHV-8 infection of cells was observed when DMSO in similar volume was used (data not shown). Taken together, these results demonstrate a well orchestrated MAPK signaling pathway initiated by Raf kinase in the target cells (Figures 1 and 2) , which was significantly inhibited by UO126 treatment. UO126 inhibited MEK1/2 and ERK1/2 activity to a significant extent in cells, but this was not enough to lower infection to zero suggesting a possible role for signaling emanating from Raf kinase, other than the traditional MEK1/24ERK1/2 pathway. Such situations have been documented where Raf signaling may transmit its signaling through more than one intermediate (Janssen et al., 1998; Baumann et al., 2000; Shelton et al., 2003) . Further, MEK inhibitors cannot suppress all the effects of Raf signaling. Hence, future studies will be directed 
Raf expression does not reactivate latent HHV-8 infection
The MAPK pathway has been shown to activate latent HIV-1 infection by its ability to regulate cytokines expression (Yang et al., 1999 (Figure 5a ), irrespective of the infection pattern ( Figure 3c ). Heparin (H) at 10 mg/ml significantly inhibited (by about 90%) the ability of GFP-HHV-8 to bind unstimulated (data not shown) and b-estradiol-stimulated HFF, HFF/DA-Raf [YY] : ER, HFF/DB-Raf [DD] :ER, and HFF/DRaf-1 [YY] :ER cells (Figure 5a ). In contrast, 10 mg/ml of chondroitin sulfate A (CSA) did not have any significant effect on binding of GFP-HHV-8 to unstimulated (data not shown) and b-estradiol-stimulated target cells (Figure 5a ). These results demonstrate that the Rafdependent signaling does not enhance the ability of virus to bind cells. Thus Raf enhances virus infection at a postattachment stage of entry.
Heparin inhibits GFP-HHV-8 infection of HFF cells expressing oncoprotein Raf
Herpesviruses engage multiple receptors during viral entry (Spear and Longnecker, 2003) . Some are binding receptors that serve to concentrate virus on the cell surface without triggering changes required for membrane fusion. Others are considered entry receptors, binding to which triggers events required for membrane fusion. HS is a binding receptor for HHV-8 (Akula et al., or CSA (1, 10, and 100 mg/ml). This mixture was added to 70-80% confluent HFF cell monolayers grown in eight-well chamber slides and incubated at 371C. After 2 h, the cells were washed three times with DMEM and further incubated with growth medium at 371C. Infection was monitored 3 DPI as per standard protocols. Data presented represent the average7s.d. of three experiments. CSA did not inhibit GFP-HHV-8 infection of HFF even when used at a concentration of 1000 mg/ml. The % inhibition of GFP-HHV-8 infection by 100 mg/ml of heparin was statistically significant (Po0.05) when compared to all other treatments by least significance difference 2001b). It has been demonstrated by us and others that HHV-8 infection can be significantly and specifically inhibited by the use of soluble heparin (when compared to other glycosaminoglycans, such as CSA, B and C) at the level of binding (Akula et al., 2001b; Birkmann et al., 2001) . Enhanced HHV-8 infection due to expression of Raf oncoproteins did not increase the amount of virus binding to target cells (Figure 5a ). Heparin at concentrations of 100 mg/ml significantly inhibited HHV-8 infection of target cells (Figure 5b ), while CSA did not significantly alter infection of cells (Figure 5b) . These results suggest that the initial stages of entry pathway are unaltered in the cells expressing Raf oncoproteins.
Raf-induced expression of HB-EGF and VEGF mRNA
The three principle features of KS tumors are angiogenesis, inflammation, and proliferation (Gallo, 1998) . The predominant cell type in a KS lesion is the spindle shaped cells (SSCs). Several cytokines/growth factors are produced in KS lesions that have a profound growth effect on SSCs. These cytokines/growth factors activate normal endothelial cells causing them to acquire phenotypic and functional features of SSCs. The major cytokines/growth factors that have been identified to play a role in KS development are interleukin-1a, and b (IL-1a, and b), tumor necrosis factor a, and b (TNFa, and b), interferon g (INFg), basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), monocyte chemotactic protein-1 (MCP-1), and IL-8 (Ensoli et al., 2000) . In vitro, KS cells generally produce IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), VEGF, platelet-derived growth factor (PDGF), and bFGF (Bailer et al., 1995; Ensoli et al., 2000) . Raf genes are known to influence the expression of growth factors (Weinstein-Oppenheimer et al., 2002) . Hence, the effects of Raf on growth factor expression profiles in target cells were examined. Our results demonstrate that Raf expression significantly altered the growth factor expression profile in HFF cells. No detectable signal was observed with reactions performed in the absence of RT or with no template (data not shown), demonstrating the specificity of the RT-PCR performed. The expression of epidermal growth factor (EGF) (Figure 6a , lane 1) was almost undetected in b-estradiol-stimulated HFF/DA-Raf [YY] :ER and HFF/DRaf-1 [YY] :ER while its expression was at comparable levels in HFF and HFF/DBRaf [DD] :ER cells; the expression of oncostatin M and GM-CSF (Figure 6a , lanes 3 and 5) was at very low and undetected levels in all of the b-estradiol-stimulated Figure 6 Effect of Raf oncoproteins on expression of growth factors. (a) RT-PCR to analyse the cytokine expression profile. HFF, HFF/DA-Raf [YY] :ER, HFF/DB-Raf [DD] :ER, and HFF/ DRaf-1 [YY] :ER were treated with 1 mM b-estradiol at 371C. After 24 h post-treatment, total RNA was isolated, reverse transcribed by RT-PCR, and the cDNA subjected to PCR analysis using primers specific to EGF, HB-EGF, oncostatin-M, VEGF, GM-CSF, PDGF-a, and the human b-actin genes. The PCR-amplified products were resolved in a 1.2% agarose gel and stained by ethidium bromide. (b, c) Northern hybridization to visualize elevated HB-EGF and VEGF expression in Raf-expressing cells. RNA from HFF, HFF/DA-Raf [YY] :ER, HFF/DB-Raf [DD] :ER, and HFF/DRaf-1 [YY] :ER were probed by Northern hybridization using DIG-labeled probe specific to HB-EGF and VEGF, respectively. Data representing the RNA expression are presented as fold increase (average7s.d. from three experiments) in the boxes below the panels cells; the expression of PDGF-a (Figure 6a , lane 6) was comparable in b-estradiol-stimulated HFF, HFF/DARaf [YY] :ER, HFF/DB-Raf [DD] :ER, and HFF/DRaf-1 [YY] :ER cells; and the expression of heparin-binding EGF-like growth factor (HB-EGF) and VEGF ( Figure 6a, lanes 2 and 4) was significantly higher in b-estradiol-stimulated HFF/DA-Raf [YY] :ER, HFF/DBRaf [DD] :ER, and HFF/DRaf-1 [YY] :ER when compared to HFF cells. The levels of b-actin in different bestradiol-stimulated cells remained unaltered (Figure 6a ). There was no significant difference observed in the cytokine expression pattern among unstimulated HFF/ DA-Raf [YY] :ER, HFF/DB-Raf [DD] :ER, and HFF/DRaf-1 [YY] :ER when compared to b-estradiol-stimulated HFF cells (Figure 6a ). Overall, there was increased expression of both VEGF and HB-EGF observed in cells expressing A-Raf, B-Raf, and Raf-1 oncoproteins.
In order to confirm the authenticity of this data, the expression of both HB-EGF and VEGF were monitored by Northern blotting. A Raf-dependent increase in the HB-EGF transcript in HFF-expressing Raf oncoproteins was detected. There was a significant increase in the mRNA expression of HB-EGF in b-estradiolstimulated HFF/DA-Raf [YY] :ER (Figure 6b (Figure 6b, lane 1) . HB-EGF mRNA expression was lowered to a significant extent (almost undetectable) in b-estradiol-stimulated HFF, HFF/DA-Raf [YY] :ER, HFF/DB-Raf [DD] :ER, and HFF/DRaf-1 [YY] :ER cells (Figure 6b , lanes 3, 6, 9, and 12) that were treated with 10 mM UO126. Similar effects of UO126 were observed in unstimulated HFF and other Raf-expressing HFF cells (data not shown). Previous studies have demonstrated such inhibitory effects of UO126 on HB-EGF mRNA expression within 30 min post-treatment (Ellis et al., 2001) . We also observed a significant increase in VEGF mRNA expression in b-estradiol-stimulated HFF/DA-Raf [YY] :ER (Figure 6c (Figure 6c, lane 3) ; and by about 3.5-fold in HFF/DA-Raf [YY] :ER, HFF/DB-Raf [DD] :ER, and HFF/DRaf-1 [YY] :ER cells (Figure 6c , lanes 6, 9, and 12). Similar effects of UO126 were observed in unstimulated HFF and other Raf-expressing HFF cells (data not shown). Previous studies have documented such inhibitory effects of UO126 on VEGF mRNA expression (Takenaka et al., 2003; Tokuda et al., 2003) . Significant differences in the levels of b-actin mRNA was not detected between respective treatments ( Figure  6b and c) , demonstrating the specificity of the effect of Raf expression of growth factors tested.
Soluble VEGF and HB-EGF significantly enhance HHV-8 infection
VEGF is an angiogenic factor expressed in KS lesions and known to play a key role in KS pathogenesis (Ensoli et al., 2000 (Ensoli et al., , 2001 Masood et al., 2002) . VEGF mediates its effect on the cells by binding with VEGF receptor-1 (VEGFR-1 or Flt-1), VEGF receptor-2 (VEGFR-2 or KDR), and VEGF receptor-3 (VEGFR-3 or Flt-4) (Bairey et al., 2004) . The expression of KDR and Flt-4 is restricted to endothelium and lymphatic endothelium, respectively (Karkkainen and Petrova, 2000; Yang et al., 2002; Bairey et al., 2004) . In contrast to KDR and Flt-4, Flt-1 is not restricted to a specific cell lineage as it is expressed in a variety of cell types (Shen et al., 1993; Wang and Keiser, 1998; Zhang et al., 2002) . HB-EGF is a potent mitogen and a chemo-attractant for many cell types (Raab and Klagsbrun, 1997) . HB-EGF mediates its activity via epidermal growth factor receptor (EGFR) (Olayioye et al., 2000) . Interestingly, HFF cells expressed both VEGFR-1 and EGFR as determined by RT-PCR (Figure 7a ). Our results showed that the HFF cells expressed very little VEGFR-2 that could not be detected by our system (Figure 7a ). No detectable signal was observed with reactions performed in the absence of RT or with no template (data not shown), demonstrating the specificity of the RT-PCR performed.
There is very little known about the role of VEGF and HB-EGF on virus entry into target cells. Since a marked enhancement in the mRNA expression of both VEGF and HB-EGF were observed in cells expressing Raf, the roles of these growth factors in virus infection of cells was examined. No detectable signal was observed with reactions performed in the absence of RT or with no template (data not shown), demonstrating the specificity of the RT-PCR performed. VEGF significantly enhanced GFP-HHV-8 infection of HFF cells (Figure 7b) . A concentration-dependent enhancement of GFP-HHV-8 infection of cells was observed after treatment with these growth factors. A maximal enhancement (4.570.5-fold in VEGF treated vs 1.0-fold in untreated) was observed with 1 mg/ml VEGF (Figure 7b) . A modest enhancement of GFP-HHV-8 infection was observed in 100 ng/ml of HB-EGF-treated cells when compared to untreated cells (2.070.15-vs 1.0-fold). Interestingly, there was a drop in infection noticed when cells were treated with concentrations of over 1 mg/ml of HB-EGF (Figure 7b) . A very significant inhibition of GFP-HHV-8 infection in HFF was observed when the cells were treated with X25 mg/ml of HB-EGF (data not shown). EGF did not alter the GFP-HHV-8 infection of HFF significantly (Figure 7b ). The specificity of the growth factor mediated enhanced HHV-8 infection was ascertained by the use of specific neutralizing antibodies.
Both anti-VEGF antibodies and anti-HB-EGF antibodies significantly neutralized VEGF and HB-EGF mediated enhanced GFP-HHV-8 infection of HFF cells, respectively (Figure 7c and d) . The enhanced virus infection mediated by VEGF (1 mg/ml) and HB-EGF (100 ng/ml) was inhibited by 51 and 91% by anti-VEGF and anti-HB-EGF, respectively (Figure 7c and d) . There was no significant inhibition of the growth factor mediated enhanced virus infection by preimmune IgG's (Figure 7c and d) . Interestingly, enhancement of HHV-8 infection in HFF cells was not observed when both VEGF and HB-EGF were added to cells 3 h postinfection (data not shown). This indicates that both VEGF and HB-EGF influenced early stages of virus entry process to enhance virus infection. The infections were also monitored and confirmed by staining for ORF73 expression by immunoperoxidase assay and RT-PCR as described above (data not shown).
Discussion
A conventional approach to study virus infection and the associated signaling transduction pathway involves using permissive cells. These experiments almost always demonstrated the abilities of what the virus could do from the point of the target cells. In this work we wanted to create a system to analyse, at least in part, the critical signaling that is offered by a cell that necessitates better and efficient infection from the virus point of view. Prior to our finding, very little work has been done on the aspect of Raf/MEK/ERK pathway and its role in virus entry except for the observation that: Borna virus infection induces a Raf/MEK/ERK signaling pathway critical for virus spread (Planz et al., 2001) ; and binding of purified human immunodeficiency virus-1 (HIV-1) virions to CD4 receptors resulted in association and tyrosine phosphorylation and activation of tyrosine kinase Lck and Raf-1. This Lck-Raf-1 pathway was hypothesized to play an essential role in the transcriptional activation of the integrated HIV-1 provirus as well as in its pathogenicity (Popik and Pitha, 1996) . In additional studies, coexpression of constitutively activated Ras, Raf, or MEK in the absence of extracellular stimuli was shown to enhance HIV-1 infection of 293T cells by fivefold (Yang et al., 1999) . However the authors did not identify the actual mechanism of how MAPK Total RNA was isolated from HFF cells, reverse transcribed by RT-PCR, and the cDNA subjected to PCR analysis using primers specific to EGFR, VEGFR-1, VEGFR-2, and the human b-actin genes. The PCR-amplified products (EGFR-349 bp; VEGFR1-305 bp) were resolved in a 1.2% agarose gel and stained by ethidium bromide. (b) VEGF and HB-EGF significantly enhances HHV-8 infection. HFF cells grown in eight-well chamber slides were treated with either DMEM alone or DMEM containing different concentrations of VEGF, HB-EGF, and EGF for 1 h at 371C. These cells were then infected with GFP-HHV-8 in either the absence or presence of VEGF, HB-EGF, and EGF, respectively, for 2 h at 371C. Infection was monitored at the end of 3 DPI as per standard procedures. Data presented represent the average7s.d. of three experiments. (c, d) VEGF and HB-EGF mediated enhanced HHV-8 infection is inhibited by specific neutralizing antibodies. Anti-human VEGF antibodies (3 mg/ml) and anti-human HB-EGF antibodies (6 mg/ml) was incubated with VEGF and HB-EGF, respectively, at 371C for 1 h. This antibody-growth factor mixture was added onto cells and incubated for 1 h at 371C. These cells were infected with GFP-HHV-8 and monitored for infection as described above. Data presented represent the average7s.d. of three experiments. Average values on the columns with different superscripts are statistically significant (Po0.05) by least significance difference pathway enhanced HIV-1 infection. Finally, there is no direct evidence of Raf activation and associated signaling pathway(s) in KS lesions. The only literature available is indirect evidence presented earlier (Faris et al., 1996) . They used cells from KS lesions and demonstrated the ability of oncostatin M to activate the JAK-STAT and the Ras/Raf/MEK/ERK pathway. Based on their findings, they proposed that the activated JAK-STAT, ERK, and JNK (activated by bFGF) pathways function synergistically to induce KS cell growth. In this report, we have provided evidence to demonstrate for the first time, the ability of Raf oncoproteins (B-Raf/Raf-1/A-Raf) to specifically enhance HHV-8 infectious entry into target cells at least in part, via modulating expression of growth factors (VEGF and HB-EGF).
VEGF is a mitogen that is required for both vasculogenesis and angiogenesis (Aoki and Tosato, 2001) . VEGF in KS development has been proposed to act synergistically with bFGF in inducing angiogenesis and edema (Bais et al., 1998; Ensoli et al., 2000; Hayward, 2003) . KS cells also express VEGF and VEGFRs and use VEGF as an autocrine/paracrine growth factor (Masood et al., 2002) . HHV-8-transformed cells express higher levels of VEGF, VEGF-C, VEGF-D, and placenta growth factor (PlGF), in addition to VEGFR-1, -2, and -3 (Masood et al., 2002) . Both HHV-8 viral G-protein coupled receptor (vGPCR) and vIL-6 have been shown to upregulate VEGF expression in fibroblasts (Bais et al., 1998; Aoki et al., 2000) . Since both vGPCR and vIL-6 genes are expressed only by a small number of cells in KS lesions when compared to latency-associated transcripts for Kaposin and LANA, it was concluded that they could not be the sole factors promoting VEGF synthesis leading to transformation (Masood et al., 2002) . However, the authors concluded that VEGF is an important determinant factor for KS and that both VEGF and VEGFR are unique targets for the treatment of KS. Our present work identifies a probable candidate, Raf, to explain the VEGF expression by KS cells. Our immediate work is towards analysing the activity of Raf in KS lesions and its role in promoting VEGF expression.
On the other hand, HB-EGF expression pattern in KS has not yet been analysed. HB-EGF was described for the first time in the conditioned medium of macrophages (Higashiyama et al., 1991) . Since then, HB-EGF has been described in endothelial (Iivanainen et al., 2003) , fibroblast (Ingram et al., 2003) , B cells (De Vos et al., 2001) , T cells (Blotnick et al., 1994) , and keratinocytes (Yoshiizumi et al., 2003) . It is synthesized as a type-1 transmembrane protein that can be shed enzymatically to release a soluble 14-20 kDa growth factor (Raab et al., 1994) . The transmembrane form of HB-EGF acts in a juxtacrine manner to signal neighboring cells (Raab et al., 1994; Higashiyama et al., 1995) , and as a receptor for diphtheria toxin and mediates DT-induced toxicity (Naglich et al., 1992) . The soluble form of HB-EGF is a potent mitogen and chemo-attractant for many cell types (Raab and Klagsbrun, 1997) . HB-EGF activity is mediated via high affinity EGF-receptor tyrosine kinases (Olayioye et al., 2000) and cell surface HS via a heparin-binding domain rich in lys and arg residues (Thompson et al., 1994) . We observed a biphasic effect of HB-EGF on HHV-8 infection of HFF cells. This is an interesting situation, given the fact that HHV-8 interacts with HS-like moieties at the early stages of entry. At lower concentrations (100 ng/ml was found to be optimum; which was at least 100 times lower concentration when compared to heparin that is required to inhibit HHV-8 infection) HB-EGF was found to be enhancing, while concentrations above 25 mg/ml (490% inhibition of virus infectivity was observed at 500 mg/ml) was found inhibitory (data not shown). We concluded that at higher concentrations HB-EGF binds HS on the target cells to exceeding levels that impair virus binding. In other words, HB-EGF competes with HHV-8 for HSbinding sites. On the contrary, heparin inhibited HHV-8 infection by competitively binding to the virus. In fact, heparin did not enhance infections at lower concentrations as HB-EGF (unpublished observations).
We demonstrated the specificity of Raf-mediated growth factor expression by the use of the MEK inhibitor UO126 that significantly inhibited expression of VEGF and HB-EGF mRNA (Figure 6b and c) . The MEK inhibitor, UO126, negatively regulated both MEK1/2 and ERK1/2 activity; and VEGF and HB-EGF mRNA expression levels, resulting in reduced HHV-8 infection of target cells. Taken together, we concluded that Raf-associated MEK1/2 signaling significantly and consistently alters growth factor expression in target cells leading to enhanced HHV-8 infection. However, at this point we are guarded in interpreting the data from the use of soluble VEGF and HB-EGF in analysing HHV-8 infection as we used several fold higher concentrations in our assay system when compared to what is achievable in a biological system. It is also unclear what signal(s) is/are responsible for the differences in the infection pattern observed in cells based on the type of Raf expression (Figure 3a-c) . Our future studies are directed towards identifying the mechanism of VEGF-mediated virus enhancement of infection, and the relationship between the physiological concentrations of VEGF and HB-EGF with respect to HHV-8 infectious entry.
Having said these, where and when would one find cells expressing oncoprotein Raf in vivo, with respect to KS lesion? To answer this question, we should understand the different stages of KS. In early stages, KS is not a true sarcoma, but a hyperplastic and reactive process. At this stage of development the cells are highly dependent on cytokines and exogenous growth factors (Ganem, 1998) . However, studies suggest the possibility of malignant nature of late-nodular KS. In fact, evidience of aneuploidy, microsatellite instability, and clonality of KS SSCs has been found in high-grade KS lesions (Ganem, 1998) . In contrast to early stages of KS, late KS also appears to be independent of growth factors and can be resistant to conventional therapy. Taken together, we hypothesize that oncoprotein Raf will be expressed in cells as KS progresses from early to late stage. Constitutive activation of the Raf signaling has vital implications in both AIDS-and non-AIDSassociated KS pathogenesis. They are (1) mutations and/or constitutive activation of Raf kinases have the potential to abrogate the cytokine dependency of cells, prevent apoptosis, and thus induce tumorigenecity in cells (Hoyle et al., 2000) , and (2) can promote spreading of HHV-8 infection leading to an increase in the number of latently infected cells, and thus enhance KS pathogenesis. In addition, Raf is known to enhance expression of integrins (Woods et al., 2001) . VEGF is also known to interact with integrins and thus aid the key process of angiogenesis (Masson-Gadais et al., 2003) . Hence, our future experiments are directed towards analysing the effect of Raf on the expression of HHV-8 entry receptors, integrins a3b1, avb3, and avb5 (Akula et al., 2002 . Future studies directed towards analysing the effect of increased expression of Raf on HIV-1, human cytomegalovirus (HCMV), HHV-6, papilloma virus, BK virus, and hepatitis virus C infection and the effect of one on another will yield valuable results. Interestingly, in addition to HHV-8 (Gallo, 1998) , HIV-1 (Gallo, 1998) , HCMV (Giraldo et al., 1980) , HHV-6 (Kempf and Adams, 1996) , papilloma virus (Adams et al., 1995) , BK virus (Monini et al., 1996) , and hepatitis virus C (Hermouet et al., 2003) are the viruses commonly observed in immuno-compromised individuals. All the proposed studies are very important with respect to understanding HHV-8 and AIDS-associated pathogenesis. The present model explaining KS pathogenesis indicates that 'HHV-8 lytic replication is a necessity for the development of KS lesions.' This is based on the following facts: (1) detection of transcripts encoding HHV-8 lytic antigens in KS tissue, and detection of herpesvirus particles in classical KS tissue by electron-microscopy (Chang et al., 1994; Ablashi et al., 2002) , (2) reduced risk of KS after ganciclovir treatment that can inhibit HHV-8 replication (De Clercq et al., 2001) , and (3) serological studies suggest the need for HHV-8 replication to precede AIDS-KS development (Chandran et al., 1998) . The two arms for the increase in HHV-8 load in KS is hypothesized to be the micro-environment provided by the aberrant growth factor production (Gallo, 1998; Ganem, 1998; Ensoli et al., 2001) , and a productive HHV-8 infection (Chang et al., 1994; Gallo, 1998; Ganem, 1998; Ensoli et al., 2001; Ablashi et al., 2002) . Our work demonstrates the ability of oncoprotein Raf to influence both these arms significantly. Recently, Raf has been targeted as a novel therapeutic strategy in cancer biology (Gorden et al., 2003; Mercer and Pritchard, 2003) . Hence, the long-term goals will be aimed at developing antiviral therapies based on targeting the Raf kinase cascade.
Our results have provided new insight into studying virus-target cell interactions as well. Earlier this year we identified HHV-8 to utilize integrin-mediated MAPK pathway of signaling during early stages of entry. However, it was a divergent signaling pathway in that HHV-8 induced predominantly a PI 3-kinase-PKC-z-MEK-ERK signaling pathway in the target cells (Naranatt et al., 2003) . However, HHV-8 infection of cells conditionally expressing Raf signaling was found to be significantly enhanced when compared to cells, which were not expressing this specific pathway of signaling. Given the situation, could HHV-8 entry into cells under normal conditions be a less efficient process? Is it a virus-mediated phenomenon? or is it dictated mainly by the host cellular signaling? With this study, we add another feather to the repertoire of oncoprotein Raf functions, and that is its ability to directly affect virus infectious entry and thus the pathogenesis. Experiments to further elucidate the consequences of Raf signaling in HHV-8 infection and pathogenesis are under way in our laboratory.
Materials and methods
Cells
HFF (Clonetics, Walkersville, MD, USA), and recombinant green fluorescent HHV-8 (GFP-HHV-8 or rKSHV.152 (Vieira et al., 2001 ) producing BCBL-1 cells (GFP-BCBL-1; HHV-8 positive and Epstein-Barr virus negative human B cells) (Vieira et al., 2001) were grown as per procedures described before (Akula et al., 2002) .
Different clones of PA317 and HFF cells expressing different Raf oncoproteins were used in this study. These cells were made using various virus constructs that have been described earlier (Hoyle et al., 2000) . The following puromycin-resistant (puro) retroviruses were used in this study: (1) pBP3DA-Raf [YY] :ER encoding the catalytic domain of murine A-Raf fused to the human estrogen-receptor-receptor (hbER) and inserted into the pBabePuro3 (pBP3; retroviral vector); (2 and 3) pBP3DA-Raf [DD] :ER and pBP3DA-Raf [FF] :ER in which the wild-type tyrosine [YY] amino acids of A-Raf at positions 299 and 300 are replaced by aspartic acid [DD] or phenylalanine [FF], respectively; (4) pBP3DB-Raf [DD] :ER encoding the catalytic domain of murine B-Raf fused to the hbER and inserted into the pBP3; (5 and 6) pBP3DB-Raf [FF] :ER and pBP3DB-Raf [YY] :ER in which the wild-type [DD] amino acids of B-Raf at positions 492 and 493 are replaced by [FF] or [YY] , respectively; (7) pBP3B-DRaf-1 [YY] :ER encoding the catalytic domain of human Raf-1 fused to the hbER and inserted into the pBP3; and (8 and 9) pBP3DRaf-1 [DD] :ER and pBP3DRaf-1 [FF] :ER in which the wild-type [YY] amino acids of Raf-1 at positions 340 and 341 are replaced by [DD] or [FF] , respectively. These activated Raf constructs lack the CR1 and CR2 domains.
The following G418-resistant (neo) retroviruses (Hoyle et al., 2000) were used in this study: (1) pLNCRaf-1 that encodes the full-length human Raf-1 cDNA inserted into the pLNCX retroviral vector, and (2) pLNCDRaf-1 that contains the same Raf-1 cDNA as described above inserted into the pLNCX retroviral vector.
Plasmid DNAs containing recombinant retroviruses were transfected into the PA317 cells with lipofectin (Invitrogen, Carlsbad, CA, USA). Both PA317 and HFF cells were infected with viral stocks as described before (Hoyle et al., 2000) . The nomenclature of the PA317 is PA317/DA-Raf:ER, PA317/DBRaf:ER, PA317/DRaf-1:ER for cells infected with the ARaf:ER, B-Raf:ER or Raf-1:ER viruses, respectively. In subscripted brackets after the particular Raf gene, are the amino acids present in the different Raf proteins at the critical phosphorylation residues [DD], [FF] , or [YY] . Similar pattern of nomenclature was followed for HFF cells. These cells were isolated by selection in DMEM medium (Invitrogen) containing 2 mg/ml puromycin (Sigma). Cells infected with the Raf-1 or DRaf-1 retroviruses contained in the pLNC vector was referred to as PA317/Raf-1 or PA317/DRaf-1, respectively. These cells were isolated in DMEM medium (Invitrogen) containing 500 mg/ml of G418. Both PA317 and HFF cells expressing Raf proteins were grown in DMEM (Invitrogen), supplemented with fetal bovine serum (FBS) (Atlanta Biologicals Inc., Lawrenceville, GA, USA), L-glutamine and antibiotics. To remove endogenous estrogens contained in FBS, all FBS used in this study was charcoal stripped. Further more, to eliminate the ability of phenolred to activate the estrogen receptor, the cells were maintained in phenol red-free DMEM.
Virus GFP-HHV-8 was used to monitor virus binding and infectious process (Vieira et al., 2001) . The construction of the recombinant HHV-8 expressing the GFP has been described elsewhere (Vieira et al., 2001) . Purification of the unlabeled and [ 3 H]thymidine GFP-HHV-8 was performed as per standard protocols using GFP-BCBL-1 cells (Akula et al., 2001a (Akula et al., , 2002 . Herpes simplex virus-type 2 (HSV-2, strain 333) grown in CV-1 cells was purified as per protocols described earlier (Akula et al., 2002) .
Infectivity assay
GFP-HHV-8 (rKSHV.152) used in these studies is not clonal and contains both wild-type and recombinant viruses (Vieira et al., 2001) . Hence, for each batch of stock virus, infectivity was first determined by estimating the number of green fluorescent cells indicative of infection, and then by performing an immunoperoxidase staining to detect HHV-8-ORF73 protein expressing cells (Akula et al., 2002) , which estimates the total number of infectious particles. HHV-8 infections were routinely performed at a multiplicity of infection (MOI) (73-IU) of one per cell . A mixed population does not deter the conclusions drawn from our experiments. Routinely, cells were grown to 70% confluency in eight-well chamber slides (Nagle Nunc International, Naperville, IL, USA). The cells were washed twice in PBS and incubated in phenol red-free DMEM medium containing 5% FBS for 24 h before growing the cells in either absence (unstimulated) or presence of 1 mM b-estradiol (stimulated) at 371C. After 24 h incubation, cells were infected either in the absence or presence of b-estradiol at 371C. After 2 h, the cells were washed twice with DMEM and further incubated with growth medium at 371C. After 3 days, slides were examined by an OLYMPUS IX50 inverted fluorescent microscope. Green fluorescent cells indicative of GFP-HHV-8 entry and infection were counted using SPOT Advanced digital imaging system (Diagnostic Instruments Inc., Sterling Heights, MI, USA). After observing the slides for GFP expressions, cells were fixed in cold acetone and tested with monoclonal anti-ORF73 antibodies by immunoperoxidase assay (Akula et al., 2002) . Gradient purified HSV-2 was used at an MOI of 1 and 5 per cell. All batches of virus stock and reagents used in the preparations were tested for the presence of endotoxin by using an endpoint chromogenic Limulus amebocyte lysate assay as recommended by the manufacturer (Charles River Laboratories, Charleston, SC, USA).
Glycosaminoglycans, inhibitors, growth factors, antibodies, and primers
Heparin (Sigma), CSA (Sigma), UO126 (Promega, Madison, WI, USA), HB-EGF (Calbiochem, San Diego, CA, USA), EGF (Calbiochem), VEGF (Calbiochem), anti-human HB-EGF antibodies (R&D systems, Inc., Minneapolis, MN, USA) and anti-human VEGF antibodies (Clone 26503.11; Sigma) were used this study. Primers for VEGFR-1, VEGFR-2 (R&D systems), and EGFR (Maxim Biotech Inc., San Francisco, CA, USA) were used in this study.
Preparation of cell extracts and analysis by Western blotting
All the buffers used in this project were made with water that was endotoxin and pyrogen free. Cell lysates were prepared from cells grown in either T25 or T75 flasks as described earlier (Chang and McCubrey, 2001 ). The protein concentration of the soluble material was estimated as per standard protocols (Akula et al., 2002) .
Equal amounts (25 mg) of protein was used in Western blotting experiments (Chang and McCubrey, 2001 ). The Western blots were routinely probed first with rabbit antiphosphor-p44/42 MAPK (Thr202/Tyr204; phosphor-ERK1/2) E10 monoclonal antibody (Cell Signaling Technology, Beverly, MA, USA). Western blots were 'stripped' for reprobing with other primary antibodies by incubation for 2 h at 681C in a buffer containing 0.2 M glycine (pH 2.5), and 1% (wt/vol) SDS. The other primary antibodies used to probe the blots were rabbit anti-p44/42 MAP kinase (ERK1/2) antibody (Cell Signaling Technology), rabbit anti-phosphor-MEK1/2 (Ser217/221) antibody (Cell Signaling Technology), rabbit anti-MEK1/2 antibody (Cell Signaling Technology), and mouse antiactin antibodies (Clone AC-74; Sigma). The bands were scanned and the band intensities were assessed using the ImageQuaNT software program (Molecular Dynamics).
Raf kinase assay
Raf kinase assays were performed as per previous protocols (Chang and McCubrey, 2001) . Briefly, 100 mg of cell lysates were incubated with anti-ER antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h and then immunoprecipitated with protein-A sepharose beads overnight at þ 41C. The immunoprecipitates were washed three times with gold lysis buffer (GLB; Chang and McCubrey, 2001 ) and then further incubated for 30 min at 301C in 15 ml of kinase reaction solution (1 mM MnCl 2 , 1mM DTT, 50 mM ATP, 10 mCi [g 32 P]ATP) and 0.5 ml of purified Raf kinase substrate, GST-MEK 1 (Upstate Biotechnology, Waltham, MA, USA). The kinase reaction was stopped by washing the immunoprecipitates five times with GLB, boiled in sample loading buffer and finally resolved in a 10% SDS-PAGE gel. The gel was dried and exposed to an X-ray film. The bands were scanned and the band intensities were assessed using the ImageQuaNT software program (Molecular Dynamics).
Radiolabeled-binding assay
Radiolabeled-binding assays were performed in PA317 and HFF cells grown in 24-well plates using [ 3 H]thymidine GFP-HHV-8 as per standard protocols (Akula et al., 2001b (Akula et al., , 2002 .
RT-PCR and Northern blotting
Unstimulated and b-estradiol-stimulated PA317 and HFF cells were both, either untreated or treated with various concentrations of UO126 at 371C for 1 h, and then infected with GFP-HHV-8 in either absence or presence of inhibitor at 371C for 2 h. These cells were washed twice with DMEM, and incubated with growth medium at 371C. After 48 h, total RNA was isolated using Nucleospin RNA II kit (Clontech, Palo Alto, CA, USA) as per the manufacturer's recommendations.
